Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564320 | 1.00 | NPSR1 (0.53) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL9082408 | 0.89 | DHODH (0.62) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3563527 | 0.88 | DHODH (0.55) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3565256 | 0.88 | DHODH (0.58) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL13885851 | 0.88 | DHODH (0.58) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3565253 | 0.88 | DHODH (0.58) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3569446 | 0.87 | MAPT (0.61) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3569444 | 0.87 | MAPT (0.61) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3568975 | 0.86 | DHODH (0.52) | NPSR1MAPTKDM4ERECQLDHODH | |
| SCHEMBL3568973 | 0.86 | DHODH (0.52) | NPSR1MAPTKDM4ERECQLDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | claimed |
| JP-2007536262-A | — | — | 2007-12-13 | — | — | JP | claimed |
| CN-1976892-A | Substituted enaminones, their derivatives and their use | UNIV CALIFORNIA (US) | 2007-06-06 | — | — | CN | claimed |
| EP-1742904-A4 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1742904-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005108347-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | WO | claimed |
| US-7825278-B2 | Substituted enaminones, their derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| CN-1976892-A | Substituted enaminones, their derivatives and their use | UNIV CALIFORNIA (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1742904-A4 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1742904-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108347-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | GABRB2, GABRB1, GABRB3 | NPSR1 81/4885MAPT 1159/4885KDM4E 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.